SAN DIEGO – Between 2020 and 2024, the number of unique sites in the United States where phase I clinical trials for non-small cell lung cancer (NSCLC) were conducted decreased by 44% and became increasingly...
All patients were negative for minimal residual disease, and no patients experienced progression to active multiple myeloma during the...
This approach may eventually help guide personalized treatment decisions for patients diagnosed with these cancers SAN DIEGO – A...
SAN DIEGO – A biology-guided artificial intelligence model applied to routine pathology slides accurately predicted outcomes and response to...
AACR’s largest-ever grant program will award 15 early-stage and mid-career investigators with $1 million each over 3 years SAN...
The investigational drug led to objective response and disease control in patients with late-stage disease SAN DIEGO – Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced...
Responses were seen in patients who were not treated with prior KRAS G12C inhibitors as well as those whose...
SAN DIEGO – The investigational KRAS G12D inhibitor zoldonrasib showed evidence of clinical activity and a favorable safety profile in patients with previously treated non-small cell lung cancer (NSCLC)...
SAN DIEGO – Long-term adverse events were rare and manageable among patients with alveolar soft part sarcoma (ASPS), which...
PHILADELPHIA – The American Association for Cancer Research (AACR) is pleased to announce the recipients of the 2026 AACR...